Genmab Completes $89M Share Buyback Program to Offset RSU Dilution
GMAB sits 53% above its 52-week low of $17.235 on light trading volume (0.1× avg).
Summary
Genmab A/S announced the completion of its share buyback program, repurchasing 342,130 shares for approximately $89 million to offset dilution from its Restricted Stock Unit program.
Key Events · Financing and Capital Events · GMAB
-
Share Buyback Program Completed
Genmab announced the completion of its share buyback program on March 13, 2026, ahead of the anticipated March 31 deadline.
-
Significant Repurchase Value
The company repurchased 342,130 shares for a total value of 615.1 million DKK (approximately $89 million USD).
-
Treasury Share Holdings Updated
Following the program, Genmab now holds 2,859,663 treasury shares, representing 4.45% of its total share capital and voting rights.
-
Offsets RSU Dilution
The buyback program was initiated to honor commitments under the company's Restricted Stock Unit (RSU) program, effectively mitigating potential dilution from employee compensation.
Analysis · GMAB · Life Sciences
This filing confirms the successful completion of Genmab's previously announced share buyback program, which aimed to repurchase shares to mitigate the dilutive effect of its Restricted Stock Unit (RSU) program. The company repurchased the full target of 342,130 shares for a total value of 615.1 million DKK (approximately $89 million USD). The completion of this program demonstrates the company's commitment to managing shareholder dilution and optimizing its capital structure. Investors should view this as a positive step in capital management.
At the time of this filing, GMAB was trading at $26.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16B. The 52-week trading range was $17.24 to $35.43. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.